Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Springworks Therapeutics Inc (NQ: SWTX ) 32.04 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 7 Open 32.04 Bid (Size) 31.89 (1) Ask (Size) 35.30 (1) Prev. Close 32.04 Today's Range 32.04 - 32.04 52wk Range 18.00 - 53.92 Shares Outstanding 49,127,913 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN August 28, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating August 21, 2024 A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. Via Investor's Business Daily Performance YTD -12.22% -12.22% 1 Month -20.69% -20.69% 3 Month -16.84% -16.84% 6 Month -32.72% -32.72% 1 Year +40.53% +40.53% More News Read More SWTX Stock Earnings: SpringWorks Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 07, 2024 Via InvestorPlace SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 07, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics: Q4 Earnings Insights February 27, 2024 Via Benzinga SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors July 29, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 July 23, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN July 01, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 05, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference May 08, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024 May 02, 2024 Via InvestorPlace SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates May 02, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting April 24, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 April 18, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire 7 Biotech Stocks to Buy as Sector Rotation Ramps Up March 13, 2024 Via InvestorPlace SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN March 04, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors February 29, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates February 27, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Present at Upcoming Investor Conferences February 22, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference January 31, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference January 08, 2024 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference December 21, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares December 08, 2023 From SpringWorks Therapeutics, Inc. Via GlobeNewswire Why SpringWorks Therapeutics Stock (SWTX) Is Nosediving December 05, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
